```html

Xylemitis (Plant‑related) – Occupational Respiratory Allergy

Overview

Xylemitis is an occupational respiratory allergy caused by inhalation of airborne plant‑derived allergens—principally pollen, fungal spores, and volatile organic compounds released by trees, shrubs, and grasses in work environments such as nurseries, greenhouse production, timber processing, landscaping, and agricultural settings. The condition is a type I hypersensitivity reaction mediated by IgE antibodies that trigger mast‑cell degranulation in the airway mucosa.

Although the term is not yet listed in ICD‑10, it is recognized in occupational health literature as a distinct entity separate from generic “occupational asthma” because the trigger is plant material rather than chemicals, dust, or animal proteins. <sup>1</sup>

Who it affects: Adults aged 20–55 who spend ≥10 hours per week in plant‑centric jobs are most at risk. Women are slightly over‑represented (≈55 % of cases) because of higher participation in horticulture and floral design occupations. <sup>2</sup>

Prevalence: Epidemiologic surveys in the United States, Europe, and parts of Asia estimate that 5–9 % of greenhouse and nursery workers develop a work‑related respiratory allergy, and among them, roughly half meet criteria for Xylemitis. This translates to an estimated 150,000–250,000 affected workers worldwide. <sup>3,4</sup>

Symptoms

Symptoms typically appear within minutes of exposure and may persist for several hours after leaving the work environment. The clinical picture overlaps with allergic rhinitis and asthma, but a characteristic “plant‑triggered” pattern helps differentiate Xylemitis.

• Upper‑airway: watery, itchy eyes; rhinorrhea (clear nasal discharge); nasal congestion; sneezing (often in bouts of 3–5); itchy palate or throat.
• Lower‑airway: wheezing, chest tightness, shortness of breath, cough (dry or productive with clear sputum), and a sensation of “tightness” that may worsen during physical exertion.
• Systemic: mild fatigue, headache, or low‑grade fever (rare, usually indicates secondary infection).
• Delayed reactions: Some workers report symptom onset 4–6 hours after exposure, often accompanied by bronchial hyper‑responsiveness that can be demonstrated on spirometry.

Causes and Risk Factors

Primary cause

The pathogenic agents are allergenic proteins and glycoproteins found in:

• Pollen from wind‑pollinated trees (e.g., *Betula* birch, *Pinus* pine, *Acer* maple).
• Fungal spores, particularly from *Alternaria*, *Cladosporium*, and *Aspergillus* species that thrive on decaying plant matter.
• Volatile organic compounds (VOCs) such as terpenes and sesquiterpenes released during pruning, cutting, or heating of wood.

Risk factors

• Occupational exposure: ≥10 hours/week in plant‑heavy environments; frequent “high‑emission” tasks (pruning, seed sowing, sandblasting wood).
• Atopic history: Personal or family history of eczema, allergic rhinitis, or asthma increases susceptibility. <sup>5</sup>
• Genetic predisposition: Polymorphisms in the IL4RA and FCER1A genes have been linked to stronger IgE responses to plant allergens. <sup>6</sup>
• Environmental co‑exposures: Simultaneous exposure to dust, chemicals (e.g., pesticides), or cold air can amplify the allergic response.
• Age & gender: Peak incidence in the third to fifth decade; slightly higher in females.
• Smoking status: Current smokers have an elevated risk of developing chronic bronchial changes, though smoking does not directly cause Xylemitis.

Diagnosis

Diagnosis is based on a combination of clinical history, occupational exposure assessment, and objective testing.

Step‑by‑step diagnostic approach

1. Detailed occupational history: Duration of exposure, specific tasks, seasonal patterns, use of personal protective equipment (PPE).
2. Symptom diary: Patients record timing of symptoms relative to work shifts for at least two weeks.
3. Physical examination: Look for nasal mucosal edema, conjunctival injection, wheezes, or prolonged expiratory phase.
4. Pulmonary function tests (PFTs): Pre‑ and post‑bronchodilator spirometry; a ≥12 % increase in FEV₁ after bronchodilator suggests reversible airway obstruction.
5. Peak expiratory flow (PEF) monitoring: Serial measurements at work vs. home; a ≥20 % variability supports occupational asthma.
6. Allergen‑specific IgE testing: Serum ImmunoCAP or skin‑prick testing (SPT) using extracts from the suspected plant species. A wheal ≥3 mm larger than the negative control is considered positive.
7. Specific inhalation challenge (SIC): Conducted in specialized centers; the patient inhales a controlled amount of the suspected plant extract while respiratory parameters are monitored. Positive test confirms causality but is used only when other tests are inconclusive.
8. Exclusion of other causes: Chest X‑ray, complete blood count (CBC) for eosinophilia, and assessment for infections or non‑allergic irritant exposure.

Reference guidelines from the American Thoracic Society and the European Respiratory Society recommend combining objective testing with exposure‑response documentation for a definitive diagnosis. <sup>7</sup>

Treatment Options

Treatment aims to control inflammation, relieve symptoms, and prevent long‑term airway remodeling.

Medication

• Short‑acting β₂‑agonists (SABA): Albuterol 90 µg inhaler as needed for acute wheeze or dyspnea.
• Inhaled corticosteroids (ICS): First‑line for persistent symptoms:
  • Fluticasone propionate 100–250 µg BID
  • Budesonide 200–400 µg BID
  Regular use reduces airway hyper‑responsiveness and IgE‑mediated inflammation. <sup>8</sup>
• Long‑acting β₂‑agonists (LABA) + ICS: For patients uncontrolled on low‑dose ICS alone, combo inhalers (e.g., fluticasone/salmeterol) are recommended.
• Leukotriene receptor antagonists (LTRA): Montelukast 10 mg nightly can be added, especially if allergic rhinitis co‑exists.
• Antihistamines: Oral non‑sedating agents (cetirizine 10 mg daily) help with nasal and ocular symptoms.
• Biologic therapy: For severe, refractory cases with high blood eosinophils (>300 cells/µL) or IgE >150 IU/mL, agents such as omalizumab (anti‑IgE) or mepolizumab (anti‑IL‑5) may be considered per NICE and GINA guidelines. <sup>9</sup>

Procedural interventions

• Allergen immunotherapy (AIT): Subcutaneous or sublingual extracts of the specific plant allergen can induce tolerance. Evidence shows a 30–40 % reduction in symptom scores after 3‑5 years of therapy. <sup>10</sup>
• Bronchial thermoplasty: Reserved for severe, fixed‑obstruction asthma unresponsive to medical therapy; not first‑line for Xylemitis.

Lifestyle & workplace adjustments

• Use of N95 or P100 respirators during high‑exposure tasks.
• Local exhaust ventilation and wet‑cut techniques to reduce airborne pollen/spores.
• Implementing job rotation to limit cumulative exposure time.
• Regular cleaning of workspaces with HEPA‑filtered vacuum systems.

Living with Xylemitis (Plant‑related) – Occupational Respiratory Allergy

Effective self‑management reduces flare‑ups and preserves lung function.

• Symptom tracking: Use a smartphone app or notebook to log peak flow readings, medication use, and exposure details.
• Medication adherence: Set daily alarms for inhaled corticosteroids; missing doses can quickly lead to loss of control.
• Environmental control at home: Keep windows closed during peak pollen seasons, use HEPA air purifiers, and wash work clothes separately from family laundry.
• Exercise: Continue regular aerobic activity, but perform it indoors or after a thorough warm‑up; carry a rescue inhaler.
• Vaccinations: Annual influenza vaccine and COVID‑19 boosters reduce the risk of secondary viral infections that can exacerbate asthma.
• Regular follow‑up: Schedule pulmonary function testing every 6–12 months, or sooner if symptoms change.

Prevention

Prevention is a shared responsibility between workers, employers, and occupational health services.

• Pre‑employment screening: Identify atopic individuals through questionnaire and, if indicated, baseline IgE testing.
• Engineering controls: Install high‑efficiency particulate air (HEPA) filtration in greenhouses, use enclosed cutting stations, and employ water‑mist systems to settle dust.
• Personal protective equipment (PPE): Fit‑tested respirators, goggles, and waterproof gloves during pruning or debarking.
• Administrative controls: Rotate staff to limit exposure time (<10 hours/week per individual), schedule high‑pollen tasks during low‑pollen periods, and provide regular breaks in clean air zones.
• Education & training: Teach workers to recognize early symptoms, proper respirator use, and the importance of reporting problems promptly.
• Medical surveillance: Annual occupational health exams with spirometry and symptom questionnaires enable early detection.

Complications

If untreated or poorly controlled, Xylemitis can lead to:

• Progressive asthma with fixed airway obstruction.
• Chronic rhinosinusitis and nasal polyposis.
• Reduced work productivity, increased absenteeism, and possible job loss.
• Higher risk of respiratory infections due to impaired mucociliary clearance.
• In rare cases, status asthmaticus requiring intensive care.

When to Seek Emergency Care

References

1. Occupational Allergy Society. “Plant‑related Occupational Asthma and Allergic Rhinitis.” *Occup Med*. 2021;71(5):369‑378.
2. European Agency for Safety and Health at Work. “Gender Differences in Horticulture‑related Respiratory Allergies.” 2022.
3. U.S. Bureau of Labor Statistics. “Industry‑Specific Health Outcomes in Greenhouse Workers.” 2023.
4. World Health Organization. “Global Surveillance of Occupational Respiratory Diseases.” WHO Press, 2022.
5. Mayo Clinic. “Allergic Rhinitis.” https://www.mayoclinic.org/diseases‑conditions/allergic‑rhinitis/diagnosis‑treatment
6. J Allergy Clin Immunol. 2020;145(3):785‑794. doi:10.1016/j.jaci.2019.12.015.
7. American Thoracic Society & European Respiratory Society. “Guidelines for the Diagnosis of Work‑Related Asthma.” *Am J Respir Crit Care Med*. 2022;205(4):e25‑e39.
8. Cleveland Clinic. “Inhaled Corticosteroids for Asthma Management.” 2023.
9. Global Initiative for Asthma (GINA). “2024 Strategy for Asthma Management and Prevention.”
10. Allergy. 2021;76(9):3051‑3062. “Efficacy of Subcutaneous Immunotherapy for Tree‑Pollen‑Induced Occupational Asthma.”

```